Human Chorionic Gonadotropin (hCG) Market by Technology (Natural Source Extraction, and Recombinant Technology), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment, and Others), and End User (Fertility Clinics, Research Institutes, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2025
- Published Date: 2020-10-18
- Report ID: 3217
- Pages: 197
-
Format:
Human Chorionic Gonadotropin (hCG) Market Overview :
The global human chorionic gonadotropin (hCG) market generated a revenue of $688 million in 2017 and is expected to reach $1,239 million by 2025, registering a CAGR of 7.6% from 2018 to 2025. hCG hormone supports the normal development of an egg in a woman's ovary and stimulates the release of the egg during ovulation. It can be extracted from the urine of pregnant women or produced from cultures of genetically modified cells using recombinant DNA technology. It is widely being used to treat infertility-related problems in women as well as increase sperm count in men. Moreover, it is used to treat cryptorchidism in young boys, a condition when the testicles have not dropped down into the scrotum normally.
Significant surge in infertility issues among men & women and increase in prevalence of hypogonadism in geriatric population drive the growth of the global hCG market. In addition, increase in awareness toward hCG among healthcare professionals and patients fuels the market growth. However, availability of substitutes and cautions & warnings issued by FDA against the side effects of hCG hamper the growth of the market. On the contrary, rise in popularity of fertility tourism and availability of advanced IVF facilities & treatment options are expected to provide lucrative opportunities for the market in the near future.
The global hCG market is segmented based on technology, therapeutic area, end user, and region. By technology, the market is bifurcated into natural source extraction and recombinant technology. Based on therapeutic area, it is classified into female infertility treatment, oligospermic treatment, male hypogonadism, and others. Depending on end user, it is segregated into fertility clinics, research institutions, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Human Chorionic Gonadotropin (hCG) Market :
The study provides an in-depth analysis of the global human chorionic gonadotropin (hCG) market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
A qualitative analysis of driving factors and opportunities helps analyze the competitive scenario of the market.
Porters Five Forces analysis is provided to interpret the bargaining power of the suppliers & buyers, threat of new entrants & substitutes, and competition among the key players.
Human Chorionic Gonadotropin (hCG) Key Market Segments :
By Technology
Natural Source Extraction
Recombinant Technology
By Therapeutic Area
Female Infertility Treatment
Male Hypogonadism
Oligospermic Treatment
Others
By End User
Fertility Clinics
Research Institutions
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
South Africa
Saudi Arabia
Rest of LAMEA
KEY MARKET PLAYERS
Bristol Myers Squibb Company
Merck & Co., Inc.
Ferring B.V.
Fresenius Kabi AG
Cigna
Sun Pharmaceutical Industries Ltd.
Lee BioSolutions, Inc.
Sanzyme
Scripps Laboratories
Lupin
The other players in the value chain include (profiles not included in the report):
Kamiya Biomedical Company
Intas Pharmaceuticals
Prospec-Tany Technogene Ltd.
Cipla Limited
Biocare Medical LLC
MyBioSource
Zydus Cadila
Life Medicare & Biotech Pvt. Ltd.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2017
3.4. Porters five forces analysis
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. High risk of hypogonadism in geriatric population
3.5.1.2. Rise in infertility rates
3.5.1.3. Increase in awareness toward hCG among healthcare professionals and patients
3.5.2. Restraints
3.5.2.1. Availability of substitutes
3.5.2.2. Cautions & warnings issued by FDA against the side effects of hCG
3.5.3. Opportunity
3.5.3.1. Rise in popularity of fertility tourism
CHAPTER 4: HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY
4.1. Overview
4.1.1. Market size and forecast
4.2. Natural source extraction
4.2.1. Key trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Recombinant technology
4.3.1. Key trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
CHAPTER 5: HUMAN CHORIONIC GONADOTROPIN MARKET, BY THERAPEUTIC AREA
5.1. Overview
5.1.1. Market size and forecast
5.2. Female infertility treatment
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Oligospermic treatment
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Male hypogonadism
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Others
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
CHAPTER 6: HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Fertility clinics
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Research institutes
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Others
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. North America market size and forecast, by country
7.2.2.1. U.S. market size and forecast, by technology
7.2.2.2. U.S. market size and forecast, by therapeutic area
7.2.2.3. U.S. market size and forecast, by end user
7.2.2.4. Canada market size and forecast, by technology
7.2.2.5. Canada market size and forecast, by therapeutic area
7.2.2.6. Canada market size and forecast, by end user
7.2.2.7. Mexico market size and forecast, by technology
7.2.2.8. Mexico market size and forecast, by therapeutic area
7.2.2.9. Mexico market size and forecast, by end user
7.2.3. North America market size and forecast, by technology
7.2.4. North America market size and forecast, by therapeutic area
7.2.5. North America market size and forecast, by end user
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Europe market size and forecast, by country
7.3.2.1. Germany market size and forecast, by technology
7.3.2.2. Germany market size and forecast, by therapeutic area
7.3.2.3. Germany market size and forecast, by end user
7.3.2.4. UK market size and forecast, by technology
7.3.2.5. UK market size and forecast, by therapeutic area
7.3.2.6. UK market size and forecast, by end user
7.3.2.7. France market size and forecast, by technology
7.3.2.8. France market size and forecast, by therapeutic area
7.3.2.9. France market size and forecast, by end user
7.3.2.10. Rest of Europe market size and forecast, by technology
7.3.2.11. Rest of Europe market size and forecast, by therapeutic area
7.3.2.12. Rest of Europe market size and forecast, by end user
7.3.3. Europe market size and forecast, by technology
7.3.4. Europe market size and forecast, by therapeutic area
7.3.5. Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Asia-Pacific market size and forecast, by country
7.4.2.1. Japan market size and forecast, by technology
7.4.2.2. Japan market size and forecast, by therapeutic area
7.4.2.3. Japan market size and forecast, by end user
7.4.2.4. China market size and forecast, by technology
7.4.2.5. China market size and forecast, by therapeutic area
7.4.2.6. China market size and forecast, by end user
7.4.2.7. India market size and forecast, by technology
7.4.2.8. India market size and forecast, by therapeutic area
7.4.2.9. India market size and forecast, by end user
7.4.2.10. Australia market size and forecast, by technology
7.4.2.11. Australia market size and forecast, by therapeutic area
7.4.2.12. Australia market size and forecast, by end user
7.4.2.13. Rest of Asia-Pacific market size and forecast, by technology
7.4.2.14. Rest of Asia-Pacific market size and forecast, by therapeutic area
7.4.2.15. Rest of Asia-Pacific market size and forecast, by end user
7.4.3. Asia-Pacific market size and forecast, by technology
7.4.4. Asia-Pacific market size and forecast, by therapeutic area
7.4.5. Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA market size and forecast, by country
7.5.2.1. Brazil market size and forecast, by technology
7.5.2.2. Brazil market size and forecast, by therapeutic area
7.5.2.3. Brazil market size and forecast, by end user
7.5.2.4. Turkey market size and forecast, by technology
7.5.2.5. Turkey market size and forecast, by therapeutic area
7.5.2.6. Turkey market size and forecast, by end user
7.5.2.7. Saudi Arabia market size and forecast, by technology
7.5.2.8. Saudi Arabia market size and forecast, by therapeutic area
7.5.2.9. Saudi Arabia market size and forecast, by end user
7.5.2.10. South Africa market size and forecast, by technology
7.5.2.11. South Africa market size and forecast, by therapeutic area
7.5.2.12. South Africa market size and forecast, by end user
7.5.2.13. Rest of LAMEA market size and forecast, by technology
7.5.2.14. Rest of LAMEA market size and forecast, by therapeutic area
7.5.2.15. Rest of LAMEA market size and forecast, by end user
7.5.3. LAMEA market size and forecast, by technology
7.5.4. LAMEA market size and forecast, by therapeutic area
7.5.5. LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. Bristol Myers Squibb Company
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.2. Ferring Pharmaceuticals Inc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.3. Merck & Co., Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. Fresenius Kabi AG
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Product portfolio
8.4.4. Business performance
8.5. Cigna
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.6. Sun Pharmaceutical Industries Ltd.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Lee BioSolutions Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.8. Sanzyme
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.9. Scripps Laboratories
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. LUPIN
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
